Management of androgenic alopecia in males.
FDA approved Finasteroids for the treatment of AGA in 1997.
Finasteroids is most common treatment approach for male AGA.
Finasteroids does not have any hormonal properties in itself and has no estrogenic, antiestrogenic, or progestational effects.
A daily dose of 1 mg is the optimum dose for treatment of AGA. It can be taken with or without food.
Finasteroids is well tolerated, and side effects occur in less than 2% of patients.
Side effects subside spontaneously in those who want to continue treatment in 59% and are reversible upon cessation of treatment.
The effect on prostate size and serum prostate-specific antigen (PSA) in this young population without BPH was small and reversible upon discontinuation.
There is no evidences of a casual link between finasteride and persistent sexual dysfunction.
It have mitogenic , nonhormonal effects on epidermal cells leading to prolonged survival time as well the capacity to induce increased proliferation on hair follicles in vitro.
The sulfotransferase enzyme (SULT1A1) activity in the hair follicle correlates with minoxidil response.
Minoxidil 5% solution or foam twice daily is approved for the treatment of AGA in men.
Mechanism of action:
Dutasteride is dual inhibitor of both types I and II 5µ-reductase that inhibits the conversion of testosterone to DHT. It is not approved by the FDA for treatment of AGA. Only in Korea has dutasteride at a dose of 0.5 mg daily been approved for treatment of AGA.
The prostaglandin F2a analogs Latanoprost and Bimatoprost are used in treating ocular hypertension and glaucoma.
A noted side effect is increased eyelash hair growth ,a feature that has been investigated in several stdies. Bimaprost is now available as a treatment for eyelash growth.
Latanoprost can be used for treatment of AGA.
Still under the experimental stage.
Book an Appointment